Comparative Study of Raltitrexed and Oxaliplatin in Metastatic Colorectal Cancer
A randomized pharmacokinetic study is underway comparing biweekly and triweekly regimens of raltitrexed and oxaliplatin in metastatic colorectal cancer.
Phase III
Oncology / Colorectal Cancer
Status
Active
Sponsor
Pfizer
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
This trial is significant as it explores a potential alternative to 5FU in treating metastatic colorectal cancer, which could reshape treatment protocols. The outcomes may influence market dynamics and competitive positioning for oncology products.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the outcomes related to objective response rate, progression-free survival, and overall survival as the trial progresses.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.